Journal profile · Medicine-Pharmacology (medical)
npj Breast Cancer
ISSN 2374-4677 · Springer Nature · ENGLAND · Founded 2015
npj Breast Cancer: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 8.38; fully open access; APC about USD 3,890; median 166 days to acceptance (102 articles, last 24 months); 167 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
npj Breast Cancer is published by Springer Nature and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics and HER2/EGFR in Cancer Research, together about 34.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
npj Breast Cancer is an open access, online-only, multidisciplinary research journal dedicated to publishing the finest research on breast cancer research and treatment.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Pharmacology (medical)
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology15.9%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology9.8%
- HER2/EGFR in Cancer ResearchMedicine9.2%
- Advanced Breast Cancer TherapiesMedicine7.8%
- Cancer Immunotherapy and BiomarkersMedicine6.3%
- Cancer Cells and MetastasisMedicine6.2%
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology4.9%
- Breast Lesions and CarcinomasMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, CNPIEC, Chinese Academy of Medical Science (CAMS), INIS Atomindex, Japanese Science and Technology Agency (JST), Meta, OCLC WorldCat Discovery Service, Ovid Discovery, SCImago, TD Net Discovery Service, Wanfang, eLibrary.ru
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 8.38LetPub ·
- CiteScore 2026-06
- 12.4LetPub ·
- SJR 2026-06
- 3.55LetPub ·
- SNIP 2026-06
- 2.05LetPub ·
- h-index
- 80OpenAlex ·
- i10-index
- 599OpenAlex ·
- 2-year mean citedness
- 6.09OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 162LetPub ·
Articles by year OpenAlex count · 1,080 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 170 | 170 | 111 |
| 2025 | 167 | 167 | 959 |
| 2024 | 107 | 107 | 1,632 |
| 2023 | 101 | 101 | 2,721 |
| 2022 | 135 | 135 | 4,933 |
| 2021 | 157 | 157 | 6,515 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
166 daysMedian, submission to acceptance · P25–P75 112 days – 238 days
- Acceptance to online
- median 17 days (102 articles)
- Submission to online
- median 184 days
- Sample
- 102 articles with submission and acceptance dates (359 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 9 weeksLetPub ·
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,290 / USD 3,890 / GBP 2,990 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,790 / EUR 3,190 / GBP 2,890 | — | — | |
| LetPub | GBP 2,690 / USD 3,490 / EUR 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
npj Breast Cancer is a fully open access journal. More on Creative Commons Attribution licenses and the benefits of publishing open access can be found in this section.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2015
- ISSN
- 2374-4677
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about npj Breast Cancer
What CAS zone is npj Breast Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, npj Breast Cancer is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of npj Breast Cancer?
The latest impact factor listed by LetPub is 8.38; CiteScore 12.4, h-index 80.
How long does peer review take at npj Breast Cancer?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 166 days (interquartile range 112–238 days); authors report an average review time of about 9 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index npj Breast Cancer?
According to LetPub and DOAJ records, npj Breast Cancer is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PubMed, Embase and CAS; that list has not been checked against each database.
Is npj Breast Cancer open access, and what is the APC?
npj Breast Cancer is a fully open-access journal. APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .